肿瘤药学Issue(1)：1-13,13.DOI:10.3969/j.issn.2095-1264.2015.001
FLT3抑制剂的抗肿瘤研发现状
Research and Development Status of FLT3 Inhibitors as Antineoplastic Drugs
摘要
Abstract
FLT3, a receptor tyrosine kinase, plays essential roles in hemopoiesis as well as the proliferation of lym-phocyte. The abnormal activated FLT3 was closely related to the development of many cancers, especially AML. As a potential target, FLT3 was intensively studied in current pharmaceutical development. Blocking FLT3 pathway provided a promising treatment for cancer. FLT3 inhibitors were registered for clinical trials, demonstrating great efficacy against can-cer. This review summarized the indication of FLT3 inhibitors and their research and development status in recent years.关键词
FLT3/抑制剂/肿瘤Key words
FLT3/Inhibitor/Cancer分类
医药卫生引用本文复制引用
姚磊,宁澄清,余聂芳..FLT3抑制剂的抗肿瘤研发现状[J].肿瘤药学,2015,(1):1-13,13.基金项目
国家自然科学基金项目资助（30873137，30772645，81172927）。 （）
